GenomeQuest CEO Richard Resnick Participates in Panel on Genomics in Clinical Trials at NGX 2011
WESTBOROUGH, Mass., September 26, 2011 – Richard Resnick, GenomeQuest’s chief executive officer, will participate in a distinguished panel on Monday, September 26, 2011, at the NGx Applying Next-Generation Sequencing/Data Management Conference in Providence, RI, titled “Genomics in Clinical Trials: Has the Time Come?”
The panel will be held Monday from 11:10 a.m. to 12:10 p.m. (ET) at the Rhode Island Conference Center and simulcast through WebEx via the following link: http://www.ngsleaders.org/Events.aspx?id=987. You must register to gain access to the webcast and teleconference. The webcast will also be available for replay after the event.
Panel Participants:
- Kevin Davies, Ph.D., Author, “The $1,000 Genome” & Editor-in-Chief, Bio-IT World (Moderator)
- Iya Khalil, Ph.D., Senior Vice President & Co-founder, GNS Healthcare
- Richard Resnick, CEO, GenomeQuest, Inc.
- Bradley L. Smith, Ph.D., Vice President, Translational Medicine, Quintiles
- Toby Bloom, Ph.D., Director, Informatics, Genome Sequencing Platform, Broad Institute of MIT and Harvard
Topics and questions addressed by this panel:
- Can these methods really lead to benefits such as streamlined recruitment, improved decision-making during trials and lower overall costs for trials?
- What can be done to accelerate adoption and success?
- What types of trials are the best candidates for these methods?
- What success stories can you share?
- Who is/should be leading the charge: pharma or their CROs?
- At what sequencing price point will genomics become mainstream in clinical trials?
Genomics applied to clinical trials has long promised immense rewards. The advanced stratification of patients into responders, non-responders and adverse responders could fundamentally lower the overall cost of trials and accelerate time-to-market for target groups. Now with plummeting costs of next-generation sequencing, increasingly affordable data storage solutions, a proliferation of analysis and inference tools that bridge the research and clinical settings and a growing volume of validated biomarkers, has the time come to realize those rewards?
While the cost of sequencing declines, use in academic, clinical, biotech and pharmaceutical labs expands, paving the way for the creation of innovative new markets for bioresearch. This panel will discuss insights in the active genome through transcription, as well as the impact of sequencing on personalized medicine.
About GenomeQuest:
GenomeQuest, the global leader in sequence data management, helps life science organizations realize the full promise of genomics. More than 160 leading health and agriculture companies, including nine of the top ten pharmaceuticals, use GenomeQuest for mission-critical work. The core technology of the company is the GQ-Engine—a sequence database engine that is purpose-built for storing, managing, and analyzing sequence data at whole- and multi-genome scale.
Learn more at www.genomequest.com.
###
Contact: Anthony Flynn, anthony flynn genomequest com
